Biochemistry, regulation and potential function of kallistatin
- PMID: 9072045
Biochemistry, regulation and potential function of kallistatin
Abstract
Components of the tissue kallikrein-kinin system include tissue kallikrein, kallistatin (kallikrein-binding protein), kininogen, kinin, bradykinin B1 and B2 receptors, and kininases. Tissue kallikrein is a serine proteinase which is capable of cleaving kininogen substrate to release the vasoactive kinin peptide. The binding of kinin to its specific receptor at target organs can produce a wide spectrum of biological effects. Kinin generation is primarily determined by the activity and availability of kallikrein since the level of kininogen is not a rate-limiting factor. Kallikrein levels are controlled by its rate of synthesis, activation, inactivation and clearance. The synthesis of tissue kallikrein is regulated transcriptionally, and its activity is regulated through post-translational processing and inactivation by inhibitors. Kallistatin is a newly discovered serine proteinase inhibitor (serpin) which forms a specific and covalently-linked complex with tissue kallikrein. Kallistatin may regulate tissue kallikrein's activity, bioavailability and clearance rate at the post-translational level. The major site of kallistatin synthesis is the liver with lower expression levels in the pancreas and kidney. Unlike many other serpins which are only present in the plasma, kallistatin is found in various tissues, cells and bodily fluids. The fact that both tissue kallikrein and kallistatin are widely distributed in tissues suggests kallistatin's role as a potential regulator of kallikrein outside the circulation. Protein purification and molecular cloning techniques have been used to study the structure, regulation and function of the components of the kallikrein-kinin system and for exploring their roles in ion transport, inflammation and blood pressure regulation. Considerable progress has been made in recent years to achieve these goals. This article provides an overview of the biochemical properties and potential physiological and pathophysiological roles of kallistatin.
Similar articles
-
Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling.Biol Chem. 2001 Jan;382(1):15-21. doi: 10.1515/BC.2001.003. Biol Chem. 2001. PMID: 11258665 Review.
-
Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence.J Biol Chem. 1992 Dec 25;267(36):25873-80. J Biol Chem. 1992. PMID: 1334488
-
Cellular localization of tissue kallikrein and kallistatin mRNAs in human kidney.Kidney Int. 1995 Sep;48(3):690-7. doi: 10.1038/ki.1995.339. Kidney Int. 1995. PMID: 7474653
-
Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli.J Biol Chem. 1993 Nov 15;268(32):24498-505. J Biol Chem. 1993. PMID: 8227002
-
The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction.Biol Chem. 2006 Jun;387(6):665-75. doi: 10.1515/BC.2006.085. Biol Chem. 2006. PMID: 16800727 Review.
Cited by
-
Kallikrein binding protein (KBP) maps to rat chromosome 6 but does not cosegregate with blood pressure in a GH x BN cross.Mamm Genome. 1997 Sep;8(9):701-3. doi: 10.1007/s003359900545. Mamm Genome. 1997. PMID: 9271680 No abstract available.
-
Protective Role of Kallistatin in Vascular and Organ Injury.Hypertension. 2016 Sep;68(3):533-41. doi: 10.1161/HYPERTENSIONAHA.116.07861. Epub 2016 Jul 18. Hypertension. 2016. PMID: 27432868 Free PMC article. Review.
-
Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).Biochimie. 2010 Nov;92(11):1546-67. doi: 10.1016/j.biochi.2010.06.022. Epub 2010 Jul 6. Biochimie. 2010. PMID: 20615447 Free PMC article. Review.
-
Kallistatin is a potent new vasodilator.J Clin Invest. 1997 Jul 1;100(1):11-7. doi: 10.1172/JCI119502. J Clin Invest. 1997. PMID: 9202051 Free PMC article.
-
Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsis.Crit Care. 2015 May 1;19(1):200. doi: 10.1186/s13054-015-0919-4. Crit Care. 2015. PMID: 25930108 Free PMC article.